ANGO News and Press, AngioDynamics Inc. From 04/02/19

The following slide deck was published by AngioDynamics, Inc. in conjunction with their 2019 Q3 earnings Read more ...

AngioDynamics ( ANGO )  Q3 results : Revenues: $86.3M (+2.9%). More news on: AngioDynamics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

AngioDynamics (NASDAQ: ANGO ): Q3 Non-GAAP EPS of $0.19 misses by $0.02 ; GAAP EPS of $0.02. More news on: AngioDynamics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Fiscal 2019 Third Quarter Highlights Net sales of $86.3 million, an increase of 3.0% year over year Gross margin declined 10 basis points year over year to 54.1% GAAP EPS of $0.02 per share; adjusted EPS of $0.19 per share Cash provided by operations of $8.3 milli...

AngioDynamics (NASDAQ: ANGO ) is scheduled to announce Q3 earnings results on Tuesday, April 2nd, before market open. The consensus EPS Estimate is $0.21 (-16.0% Y/Y) and the consensus Revenue Estimate is $88.3M (+5.3% Y/Y). Over the last 2 years, ango has beaten EPS estimates 50% of...

ANGO , LW , WBA For Seeking Alpha's full earnings season calendar, click here . More news on: AngioDynamics, Inc., Lamb Weston Holdings, Inc., Walgreens Boots Alliance, Inc., Earnings news and commentary,

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the 18 ...

The FDA approves AngioDynamics' (NASDAQ: ANGO ) investigational device exemption (IDE) application for NanoKnife Irreversible Electroporation “Direct IRE Cancer Treatment” clinical study ((DIRECT)). More news on: AngioDynamics, Inc., Healthcare stocks news, Read more .....

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration (FDA) approved the Company’s investigational devic...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration (FDA) granted an expanded 510(k) clearance for the OARtr...